For the Inventor, By the Inventor

Enter assignee name

Wilmington, DE, United States of America

Prelude Therapeutics Incorporated

USPTO Granted Patents = 18

EPO Patents = 3

Trademarks = 2

Forward Citations = 12

Loading Chart...

Loading Chart...

28 inventors (with patents filed for the assignee):

Juan Luengo (11 out of 14 patents)

Hong Lin (11 out of 14 patents)

Michael Hawkins (9 out of 30 patents)

4. Rupa S Shetty (9 out of 11 patents)

5. Andrew Paul Combs (7 out of 127 patents)

6. Philip Michael Pitis (6 out of 56 patents)

7. Gisela Saborit Villarroya (5 out of 5 patents)

8. Jincong Zhuo (3 out of 76 patents)

9. Liang Lu (3 out of 32 patents)

10. Raul A Leal (3 out of 3 patents)

11. Xiaowei Wu (3 out of 3 patents)

12. Rupa Shetty (3 out of 4 patents)

13. Andrew W Buesking (2 out of 22 patents)

14. Sarah Pawley (2 out of 2 patents)

15. Ryan Holmes (2 out of 2 patents)

18 patents: Sort by Forward Citations

1. 12459950 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2025-11-04),

2. 12448389 - BRM targeting compounds and associated methods of use (2025-10-21),

3. 12440506 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2025-10-14),

4. 12414953 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2025-09-16),

5. 12129262 - CDK inhibitors and their use as pharmaceuticals (2024-10-29),

6. 11939340 - CDK inhibitors and their use as pharmaceuticals (2024-03-26),

7. 11702423 - BRM targeting compounds and associated methods of use (2023-07-18),

8. 11685744 - CDK inhibitors and their use as pharmaceuticals (2023-06-27),

9. 11673893 - CDK inhibitors and their use as pharmaceuticals (2023-06-13),

10. 11524962 - Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5) (2022-12-13),

11. 11254683 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2022-02-22),

12. 11220524 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2022-01-11),

13. 11214574 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2022-01-04),

14. 11208416 - Selective inhibitors of protein arginine methytransterase 5 (PRMT5) (2021-12-28),

15. 11130769 - Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein (2021-09-28),

Prelude Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule therapies targeting key drivers of cancer. Their innovative approach utilizes a proprietary platform to identify and advance novel drug candidates. Prelude Therapeutics aims to revolutionize cancer treatment by bringing breakthrough medicines to patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

18 Patents

#216 in Wilmington, DE

#279 in Delaware

#17,414 in US

#33,185 in the World

Wilmington, DE, United States of America

Prelude Therapeutics Incorporated

Forward Citations = 12

28 inventors:

Juan Luengo (11 out of 14 patents)

Hong Lin (11 out of 14 patents)

Michael Hawkins (9 out of 30 patents)

4. Rupa S Shetty (9 out of 11 patents)

5. Andrew Paul Combs (7 out of 127 patents)

Please report any incorrect information to support@idiyas.com

Loading…